Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information
MOON SHOTS PROGRAM
Multiple myeloma is a blood cancer caused by rogue plasma cells that accumulate in the bone marrow. They affect the normal production of other blood cells leading to anemia and improper functioning of the immune system. They also cause bone lesions, bone destruction and an accumulation of M-protein which can lead to kidney damage. While treatment advances have improved clinical outcomes for patients with standard-risk symptomatic disease, high-risk multiple myeloma remains an urgent area with unmet therapeutic needs.
The High-Risk Multiple Myeloma Moon Shot® is working to rapidly adapt pre-clinical findings into treatment options for high-risk multiple myeloma. Our experts are working to predict disease progression for patients with precursor states, including MGUS and smoldering myeloma, with the ultimate goal of creating treatments that delay or stop disease progression in its tracks. The team is also exploring treatments such as immunotherapy and natural killer cells for patients with symptomatic high-risk myeloma.
Elisabet Manasanch, M.D.
Associate Professor, Lymphoma/Myeloma
Robert Orlowski, M.D., Ph.D.
Professor, Lymphoma/Myeloma and Experimental Therapeutics
"Even small donations, when put together, can make a huge difference and be flipped into much larger research efforts to make lives of myeloma patients better."
Listen as Moon Shot® co-leader Robert Orlowski, M.D., Ph.D., explains how your generous gift can make an impact on High-Risk Multiple Myeloma Moon Shot research projects.
High-Risk Multiple Myeloma Moon Shot® co-leader Robert Orlowski, M.D., Ph.D. discusses how the program is working to understand and treat asymptomatic high-risk multiple myeloma, and developing novel therapeutic options for patients with advanced, symptomatic disease.
Learn moreA gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by MD Anderson.
